Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balstilimab +/- Zalifrelimab in Angiosarcoma
NCT04607200Phase 2Withdrawn
- Sponsor
- Agenus Inc.
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of balstilimab in angiosarcoma (3 arms), sponsored by Agenus Inc. Primary endpoint: Response Rate at 48 months. Planned start Feb 2021; status: withdrawn.
02
Drugs
balstilimab
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT04607200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607200.